Monoclonal antibodies and cell surface antigens for the detection and treatment of small cell lung cancer (sclc)
CA 2427643 C · Owner: Immunocellular Therapeutics, Ltd. · Inventors: Gelber, Cohava
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention provides new monoclonal antibodies and binding fragments thereof which recognize and immunoreact with cell surface antigens found on small cell lung cancer (SCLC) cells. The antibodies have tumor specificity and are useful for therapy, diagnosis, monitoring, detecting and imaging of SCLC disease and of patients having SCLC disease. The antibody-recognized SCLC-specific surface antigens can serve as targets for detecting diagnosing, inhibiting or killing , SCLC cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed November 1, 2001 and granted April 15, 2014. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended November 1, 2021.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by November 1, 2023.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.